
    
      This study is a multi-center retrospective observational study. It aims to evaluate the
      effectiveness and safety of polatuzumab vedotin treatment in patients with hematopoietic stem
      cell transplantation ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R
      DLBCL), who met the criteria to access Pola through the compassionate use program (CUP).
      Based on the medical records of patients in the four participating hospitals, the study
      database will be established by using the unified case report form (CRF) to search extract
      information the data of target population from the hospital database, that is, the variables
      without personal identification information.
    
  